Molecular Profile | FGFR2 amp FGFR2-COL14A1 |
Therapy | Derazantinib |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | FGFR2 amp FGFR2-COL14A1 | colon cancer | sensitive | Derazantinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of colon cancer cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture and in cell line xenograft models (PMID: 27627808). | 27627808 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(27627808) | Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. | Full reference... |